International Brand Name:
In treatment of:
Management of Hyper Tension(HTN)
1. Excessive urination
2. Altered electrolyte balance
9. ECG Abnormality
10. Increased cough
14. Sore Throat
16. Chest Pain
1. Hypersensitivity to Torsemide and other sulfonylurea derivatives
2. Patient with anuria
1. Monitor fluid and electrolyte balance
Anticoagulants: Activity of anticoagulants may be enhanced.
Aminoglycoside antibiotics: Frusemide increases potential for ototoxicity.
Cisplatin: Frusemide increases potential for ototoxicity.
Digitalis glycosides: Diuretics induced potassium loss may precipitate digitalis toxicity, increased frequency of cardiac arrhythmias.
NSAIDs: Effect of frusemide reduced.
Lithium: Therapeutic and toxic effects of lithium increased.
Metolazone: Profound diuresis and greater than predicted electrolyte loss related to the ability of metolazone to block proximal tubular sodium reabsorption useful in patients refractory to frusemide.
Non-depolarizing muscle relaxants: Action of succinylcholine & tubocurarine potentiated by low doses reversed by high doses.
Food: Efficacy reduced when administered with food.
Propranolol: Plasma propranolol level may be increased.
Clofibrate: Increased diuretic responses.
Hydantoins: May decrease the diuretic effects.
1. In heart failure: 10 - 20 mg once daily if sufficient therapeutic response is not obtained then increases the dose until response is obtained up to 200 mg/ day.
2. In chronic renal failure: 20 mg once daily if sufficient therapeutic response is not obtained then increases the dose until response is obtained up to 200 mg/ day.
3. In hepatic cirrhosis: 5 - 10 mg once daily with potassium sparing antagonist if sufficient therapeutic response is not obtained then increases the dose until response is obtained up to 40 mg/ day.
Intravenous: Same as oral dose
Hypertension: 5 mg / day if needed dose can be gradually increased to 10mg
Children: Not recommended